Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.
复制标题
DOI：
10.1016/j.jbior.2022.100901
复制
发表时间：
2022-12
影响因子：
--
通讯作者：
Landray, Martin
中科院分区：
文献类型：
--
作者：
Peto, Leon;Horby, Peter;Landray, Martin
COVID-19治疗随机评估（RECOVERY）试验于二零二零年三月设立，以评估因COVID-19住院的人士的治疗。为了最大限度地增加招募人数，它被设计成适合整个英国的常规临床护理，因此它招募的患者比任何其他COVID-19治疗试验都多。RECOVERY已经证明了四种药物可以挽救生命-地塞米松，托珠单抗，baricitinib和casirivimab-imdevimab -还有六种药物被证明几乎没有或没有益处。在每一种情况下，“复苏”的结果都足够清晰，足以迅速影响全球实践。这一成功的部分原因与其在SARS-CoV-2大流行期间在英国的特殊背景有关，但许多原因可以推广到其他情况。特别是，它的重点是招募大量患者，以确定或排除中等但有价值的治疗益处，以及随之而来的设计决策。类似的大型精简试验可以为许多其他常见疾病的治疗提供类似的明确答案。
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial was set up in March 2020 to evaluate treatments for people hospitalised with COVID-19. To maximise recruitment it was designed to fit into routine clinical care throughout the UK, and as a result it has enrolled more patients than any other COVID-19 treatment trial. RECOVERY has shown four drugs to be life-saving – dexamethasone, tocilizumab, baricitinib and casirivimab-imdevimab – and a further six have been shown to be of little or no benefit. In each case, results from RECOVERY were clear enough to rapidly influence global practice. Some of the reasons for this success relate to its particular setting in the UK during the SARS-CoV-2 pandemic, but many are generalisable to other contexts. In particular, its focus on recruiting large numbers of patients to identify or rule out moderate but worthwhile benefits of treatment, and the design decisions that followed from this. Similar large streamlined trials could produce similarly clear answers about the treatment of many other common diseases.
登录
查看更多内容
DOI：
10.1056/nejmoa2116846
发表时间：
2022-01-27
期刊：
The New England journal of medicine
影响因子：
--
作者：
Gottlieb RL;Vaca CE;Paredes R;Mera J;Webb BJ;Perez G;Oguchi G;Ryan P;Nielsen BU;Brown M;Hidalgo A;Sachdeva Y;Mittal S;Osiyemi O;Skarbinski J;Juneja K;Hyland RH;Osinusi A;Chen S;Camus G;Abdelghany M;Davies S;Behenna-Renton N;Duff F;Marty FM;Katz MJ;Ginde AA;Brown SM;Schiffer JT;Hill JA;GS-US-540-9012 (PINETREE) Investigators
通讯作者：
GS-US-540-9012 (PINETREE) Investigators
影响因子：
11.8
作者：
Garibaldi, Brian T.;Wang, Kunbo;Xu, Yanxun
通讯作者：
Xu, Yanxun
DOI：
10.7861/fhj.2021-0083
发表时间：
2021-07-01
期刊：
Future healthcare journal
影响因子：
--
作者：
Pessoa-Amorim, Guilherme;Campbell, Mark;Haynes, Richard
通讯作者：
Haynes, Richard
影响因子：
3.7
作者：
Axfors C;Janiaud P;Schmitt AM;Van't Hooft J;Smith ER;Haber NA;Abayomi A;Abduljalil M;Abdulrahman A;Acosta-Ampudia Y;Aguilar-Guisado M;Al-Beidh F;Alejandria MM;Alfonso RN;Ali M;AlQahtani M;AlZamrooni A;Anaya JM;Ang MAC;Aomar IF;Argumanis LE;Averyanov A;Baklaushev VP;Balionis O;Benfield T;Berry S;Birocco N;Bonifacio LB;Bowen AC;Bown A;Cabello-Gutierrez C;Camacho B;Camacho-Ortiz A;Campbell-Lee S;Cao DH;Cardesa A;Carnate JM;Castillo GJJ;Cavallo R;Chowdhury FR;Chowdhury FUH;Ciccone G;Cingolani A;Climacosa FMM;Compernolle V;Cortez CFN;Costa Neto A;D'Antico S;Daly J;Danielle F;Davis JS;De Rosa FG;Denholm JT;Denkinger CM;Desmecht D;Díaz-Coronado JC;Díaz Ponce-Medrano JA;Donneau AF;Dumagay TE;Dunachie S;Dungog CC;Erinoso O;Escasa IMS;Estcourt LJ;Evans A;Evasan ALM;Fareli CJ;Fernandez-Sanchez V;Galassi C;Gallo JE;Garcia PJ;Garcia PL;Garcia JA;Garigliany M;Garza-Gonzalez E;Gauiran DTV;Gaviria García PA;Giron-Gonzalez JA;Gómez-Almaguer D;Gordon AC;Gothot A;Grass Guaqueta JS;Green C;Grimaldi D;Hammond NE;Harvala H;Heralde FM;Herrick J;Higgins AM;Hills TE;Hines J;Holm K;Hoque A;Hoste E;Ignacio JM;Ivanov AV;Janssen M;Jennings JH;Jha V;King RAN;Kjeldsen-Kragh J;Klenerman P;Kotecha A;Krapp F;Labanca L;Laing E;Landin-Olsson M;Laterre PF;Lim LL;Lim J;Ljungquist O;Llaca-Díaz JM;López-Robles C;López-Cárdenas S;Lopez-Plaza I;Lucero JAC;Lundgren M;Macías J;Maganito SC;Malundo AFG;Manrique RD;Manzini PM;Marcos M;Marquez I;Martínez-Marcos FJ;Mata AM;McArthur CJ;McQuilten ZK;McVerry BJ;Menon DK;Meyfroidt G;Mirasol MAL;Misset B;Molton JS;Mondragon AV;Monsalve DM;Moradi Choghakabodi P;Morpeth SC;Mouncey PR;Moutschen M;Müller-Tidow C;Murphy E;Najdovski T;Nichol AD;Nielsen H;Novak RM;O'Sullivan MVN;Olalla J;Osibogun A;Osikomaiya B;Oyonarte S;Pardo-Oviedo JM;Patel MC;Paterson DL;Peña-Perez CA;Perez-Calatayud AA;Pérez-Alba E;Perkina A;Perry N;Pouladzadeh M;Poyato I;Price DJ;Quero AKH;Rahman MM;Rahman MS;Ramesh M;Ramírez-Santana C;Rasmussen M;Rees MA;Rego E;Roberts JA;Roberts DJ;Rodríguez Y;Rodríguez-Baño J;Rogers BA;Rojas M;Romero A;Rowan KM;Saccona F;Safdarian M;Santos MCM;Sasadeusz J;Scozzari G;Shankar-Hari M;Sharma G;Snelling T;Soto A;Tagayuna PY;Tang A;Tatem G;Teofili L;Tong SYC;Turgeon AF;Veloso JD;Venkatesh B;Ventura-Enriquez Y;Webb SA;Wiese L;Wikén C;Wood EM;Yusubalieva GM;Zacharowski K;Zarychanski R;Khanna N;Moher D;Goodman SN;Ioannidis JPA;Hemkens LG
通讯作者：
Hemkens LG
影响因子：
2.7
作者：
Million, Matthieu;Lagier, Jean-Christophe;Raoult, Didier
通讯作者：
Raoult, Didier